| Literature DB >> 480951 |
A U Buzdar, G R Blumenschein, T L Smith, C K Tashima, G N Hortobagyi, H Y Yap, J U Gutterman, E M Hersh, E A Gehan.
Abstract
A combination of 5-fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC-BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P less than 0.01). Estimated 2-year survival rate from first recurrence was 85% for the FAC-BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease-free interval from the first recurrence, but additional follow-up is needed to determine its effect on long-term survival.Entities:
Mesh：
Substances：
Year: 1979 PMID： 480951 DOI： 10.1002/jso.2930120105
Source DB: PubMed Journal: J Surg Oncol ISSN： 0022-4790 Impact factor: 3.454